Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.676
-0.017 (-2.52%)
At close: Feb 21, 2025, 4:00 PM
0.700
+0.024 (3.54%)
After-hours: Feb 21, 2025, 7:58 PM EST
Lineage Cell Therapeutics Market Cap
Lineage Cell Therapeutics has a market cap or net worth of $154.34 million as of February 21, 2025. Its market cap has decreased by -20.53% in one year.
Market Cap
154.34M
Enterprise Value
124.38M
1-Year Change
-20.53%
Ranking
Category
Stock Price
$0.68
Market Cap Chart
Since December 1, 1998, Lineage Cell Therapeutics's market cap has increased from $147.40M to $154.34M, an increase of 4.71%. That is a compound annual growth rate of 0.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 21, 2025 | 127.70M | 34.70% |
| Dec 31, 2024 | 94.80M | -50.29% |
| Dec 29, 2023 | 190.70M | -4.12% |
| Dec 30, 2022 | 198.90M | -51.84% |
| Dec 31, 2021 | 413.00M | 56.44% |
| Dec 31, 2020 | 264.00M | 98.05% |
| Dec 31, 2019 | 133.30M | 15.01% |
| Dec 31, 2018 | 115.90M | -57.51% |
| Dec 29, 2017 | 272.80M | -26.90% |
| Dec 30, 2016 | 373.20M | -4.09% |
| Dec 31, 2015 | 389.10M | 25.52% |
| Dec 31, 2014 | 310.00M | 28.15% |
| Dec 31, 2013 | 241.90M | 51.38% |
| Dec 31, 2012 | 159.80M | -45.26% |
| Dec 30, 2011 | 291.90M | -26.38% |
| Dec 31, 2010 | 396.50M | 181.41% |
| Dec 31, 2009 | 140.90M | 234.68% |
| Dec 31, 2008 | 42.10M | 347.87% |
| Dec 31, 2007 | 9.40M | 54.10% |
| Dec 29, 2006 | 6.10M | 10.91% |
| Dec 30, 2005 | 5.50M | -79.55% |
| Dec 31, 2004 | 26.90M | 43.09% |
| Dec 31, 2003 | 18.80M | -10.05% |
| Dec 31, 2002 | 20.90M | -60.79% |
| Dec 31, 2001 | 53.30M | -37.37% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 784.71B |
| UnitedHealth Group | 429.24B |
| Novo Nordisk | 391.83B |
| Johnson & Johnson | 390.76B |
| AbbVie | 356.74B |
| Abbott Laboratories | 234.01B |
| AstraZeneca | 229.50B |
| Merck & Co. | 226.40B |